{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:47:22Z","timestamp":1777931242096,"version":"3.51.4"},"publisher-location":"Singapore","reference-count":75,"publisher":"Springer Singapore","isbn-type":[{"value":"9789811687013","type":"print"},{"value":"9789811687020","type":"electronic"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1007\/978-981-16-8702-0_8","type":"book-chapter","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T09:02:54Z","timestamp":1649754174000},"page":"123-135","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Influenza Virus Entry inhibitors"],"prefix":"10.1007","author":[{"given":"Jie","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,13]]},"reference":[{"issue":"10","key":"8_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076363","volume":"8","author":"A Antanasijevic","year":"2013","unstructured":"Antanasijevic A, Cheng H, Wardrop DJ, Rong L, Caffrey M (2013) Inhibition of influenza H7 hemagglutinin-mediated entry. PLoS One 8(10):e76363. https:\/\/doi.org\/10.1371\/journal.pone.0076363","journal-title":"PLoS One"},{"issue":"1","key":"8_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jcv.2009.11.003","volume":"47","author":"T Baranovich","year":"2010","unstructured":"Baranovich T, Saito R, Suzuki Y, Zaraket H, Dapat C, Caperig-Dapat I, Oguma T, Shabana II, Saito T, Suzuki H (2010) Emergence of H274Y oseltamivir-resistant A(H1N1) influenza viruses in Japan during the 2008-2009 season. J Clin Virol 47(1):23\u201328. https:\/\/doi.org\/10.1016\/j.jcv.2009.11.003","journal-title":"J Clin Virol"},{"issue":"9","key":"8_CR3","doi-asserted-by":"publisher","first-page":"e01567","DOI":"10.1128\/jvi.01567-19","volume":"94","author":"KN Barnard","year":"2020","unstructured":"Barnard KN, Alford-Lawrence BK, Buchholz DW, Wasik BR, LaClair JR, Yu H, Honce R, Ruhl S, Pajic P, Daugherity EK, Chen X, Schultz-Cherry SL, Aguilar HC, Varki A, Parrish CR (2020) Modified sialic acids on mucus and erythrocytes inhibit influenza A virus hemagglutinin and neuraminidase functions. J Virol 94(9):e01567. https:\/\/doi.org\/10.1128\/jvi.01567-19","journal-title":"J Virol"},{"issue":"5","key":"8_CR4","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1021\/acsinfecdis.6b00194","volume":"3","author":"A Basu","year":"2017","unstructured":"Basu A, Komazin-Meredith G, McCarthy C, Antanasijevic A, Cardinale SC, Mishra RK, Barnard DL, Caffrey M, Rong L, Bowlin TL (2017) Molecular mechanism underlying the action of influenza A virus fusion inhibitor MBX2546. ACS Infect Dis 3(5):330\u2013335. https:\/\/doi.org\/10.1021\/acsinfecdis.6b00194","journal-title":"ACS Infect Dis"},{"issue":"10","key":"8_CR5","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1086\/522609","volume":"196","author":"JA Belser","year":"2007","unstructured":"Belser JA, Lu X, Szretter KJ, Jin X, Aschenbrenner LM, Lee A, Hawley S, Kim DH, Malakhov MP, Yu M, Fang F, Katz JM (2007) DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J Infect Dis 196(10):1493\u20131499. https:\/\/doi.org\/10.1086\/522609","journal-title":"J Infect Dis"},{"issue":"12","key":"8_CR6","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1021\/bi00063a007","volume":"32","author":"DL Bodian","year":"1993","unstructured":"Bodian DL, Yamasaki RB, Buswell RL, Stearns JF, White JM, Kuntz ID (1993) Inhibition of the fusion-inducing conformational change of influenza hemagglutinin by benzoquinones and hydroquinones. Biochemistry 32(12):2967\u20132978. https:\/\/doi.org\/10.1021\/bi00063a007","journal-title":"Biochemistry"},{"issue":"10","key":"8_CR7","doi-asserted-by":"publisher","first-page":"997","DOI":"10.2174\/092986708784049658","volume":"15","author":"YS Boriskin","year":"2008","unstructured":"Boriskin YS, Leneva IA, P\u00e9cheur EI, Polyak SJ (2008) Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. Curr Med Chem 15(10):997\u20131005. https:\/\/doi.org\/10.2174\/092986708784049658","journal-title":"Curr Med Chem"},{"issue":"3","key":"8_CR8","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1128\/aac.04623-14","volume":"59","author":"RA Byrn","year":"2015","unstructured":"Byrn RA, Jones SM, Bennett HB, Bral C, Clark MP, Jacobs MD, Kwong AD, Ledeboer MW, Leeman JR, McNeil CF, Murcko MA, Nezami A, Perola E, Rijnbrand R, Saxena K, Tsai AW, Zhou Y, Charifson PS (2015) Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit. Antimicrob Agents Chemother 59(3):1569\u20131582. https:\/\/doi.org\/10.1128\/aac.04623-14","journal-title":"Antimicrob Agents Chemother"},{"issue":"26","key":"8_CR9","doi-asserted-by":"publisher","first-page":"14306","DOI":"10.1073\/pnas.94.26.14306","volume":"94","author":"CM Carr","year":"1997","unstructured":"Carr CM, Chaudhry C, Kim PS (1997) Influenza hemagglutinin is spring-loaded by a metastable native conformation. Proc Natl Acad Sci U S A 94(26):14306\u201314313. https:\/\/doi.org\/10.1073\/pnas.94.26.14306","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"8_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0062482","volume":"8","author":"TY Chen","year":"2013","unstructured":"Chen TY, Chen DY, Wen HW, Ou JL, Chiou SS, Chen JM, Wong ML, Hsu WL (2013) Inhibition of enveloped viruses infectivity by curcumin. PLoS One 8(5):e62482. https:\/\/doi.org\/10.1371\/journal.pone.0062482","journal-title":"PLoS One"},{"issue":"7","key":"8_CR11","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1021\/acs.molpharmaceut.0c00244","volume":"17","author":"Y Chen","year":"2020","unstructured":"Chen Y, Wang X, Zhu Y, Si L, Zhang B, Zhang Y, Zhang L, Zhou D, Xiao S (2020) Synthesis of a hexavalent betulinic acid derivative as a hemagglutinin-targeted influenza virus entry inhibitor. Mol Pharm 17(7):2546\u20132554. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.0c00244","journal-title":"Mol Pharm"},{"issue":"10","key":"8_CR12","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1001\/jama.2009.294","volume":"301","author":"NJ Dharan","year":"2009","unstructured":"Dharan NJ, Gubareva LV, Meyer JJ, Okomo-Adhiambo M, McClinton RC, Marshall SA, St George K, Epperson S, Brammer L, Klimov AI, Bresee JS, Fry AM (2009) Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 301(10):1034\u20131041. https:\/\/doi.org\/10.1001\/jama.2009.294","journal-title":"JAMA"},{"issue":"3","key":"8_CR13","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.bbrc.2010.05.161","volume":"397","author":"L Du","year":"2010","unstructured":"Du L, Zhao G, Zhang X, Liu Z, Yu H, Zheng BJ, Zhou Y, Jiang S (2010) Development of a safe and convenient neutralization assay for rapid screening of influenza HA-specific neutralizing monoclonal antibodies. Biochem Biophys Res Commun 397(3):580\u2013585. https:\/\/doi.org\/10.1016\/j.bbrc.2010.05.161","journal-title":"Biochem Biophys Res Commun"},{"key":"8_CR14","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1099\/vir.0.059477-0","volume":"95","author":"TO Edinger","year":"2014","unstructured":"Edinger TO, Pohl MO, Stertz S (2014) Entry of influenza A virus: host factors and antiviral targets. J Gen Virol 95:263\u2013277. https:\/\/doi.org\/10.1099\/vir.0.059477-0","journal-title":"J Gen Virol"},{"issue":"9","key":"8_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1001099","volume":"6","author":"T Eierhoff","year":"2010","unstructured":"Eierhoff T, Hrincius ER, Rescher U, Ludwig S, Ehrhardt C (2010) The epidermal growth factor receptor (EGFR) promotes uptake of influenza A viruses (IAV) into host cells. PLoS Pathog 6(9):e1001099. https:\/\/doi.org\/10.1371\/journal.ppat.1001099","journal-title":"PLoS Pathog"},{"issue":"5924","key":"8_CR16","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1126\/science.1171491","volume":"324","author":"DC Ekiert","year":"2009","unstructured":"Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M, Goudsmit J, Wilson IA (2009) Antibody recognition of a highly conserved influenza virus epitope. Science 324(5924):246\u2013251. https:\/\/doi.org\/10.1126\/science.1171491","journal-title":"Science"},{"issue":"6044","key":"8_CR17","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1126\/science.1204839","volume":"333","author":"DC Ekiert","year":"2011","unstructured":"Ekiert DC, Friesen RH, Bhabha G, Kwaks T, Jongeneelen M, Yu W, Ophorst C, Cox F, Korse HJ, Brandenburg B, Vogels R, Brakenhoff JP, Kompier R, Koldijk MH, Cornelissen LA, Poon LL, Peiris M, Koudstaal W, Wilson IA, Goudsmit J (2011) A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333(6044):843\u2013850. https:\/\/doi.org\/10.1126\/science.1204839","journal-title":"Science"},{"issue":"7","key":"8_CR18","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/infdis\/jiy547","volume":"219","author":"RW Finberg","year":"2019","unstructured":"Finberg RW, Lanno R, Anderson D, Fleischhackl R, van Duijnhoven W, Kauffman RS, Kosoglou T, Vingerhoets J, Leopold L (2019) Phase 2b study of pimodivir (JNJ-63623872) as monotherapy or in combination with oseltamivir for treatment of acute uncomplicated seasonal influenza A: TOPAZ trial. J Infect Dis 219(7):1026\u20131034. https:\/\/doi.org\/10.1093\/infdis\/jiy547","journal-title":"J Infect Dis"},{"issue":"45","key":"8_CR19","doi-asserted-by":"publisher","first-page":"11613","DOI":"10.1073\/pnas.1811345115","volume":"115","author":"DH Goldhill","year":"2018","unstructured":"Goldhill DH, Te Velthuis AJW, Fletcher RA, Langat P, Zambon M, Lackenby A, Barclay WS (2018) The mechanism of resistance to favipiravir in influenza. Proc Natl Acad Sci U S A 115(45):11613\u201311618. https:\/\/doi.org\/10.1073\/pnas.1811345115","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"8_CR20","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/s1473-3099(14)70717-0","volume":"14","author":"J Haffizulla","year":"2014","unstructured":"Haffizulla J, Hartman A, Hoppers M, Resnick H, Samudrala S, Ginocchio C, Bardin M, Rossignol JF (2014) Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b\/3 trial. Lancet Infect Dis 14(7):609\u2013618. https:\/\/doi.org\/10.1016\/s1473-3099(14)70717-0","journal-title":"Lancet Infect Dis"},{"key":"8_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.antiviral.2014.01.015","volume":"104","author":"J Hoffmann","year":"2014","unstructured":"Hoffmann J, Schneider C, Heinbockel L, Brandenburg K, Reimer R, Gabriel G (2014) A new class of synthetic anti-lipopolysaccharide peptides inhibits influenza A virus replication by blocking cellular attachment. Antivir Res 104:23\u201333. https:\/\/doi.org\/10.1016\/j.antiviral.2014.01.015","journal-title":"Antivir Res"},{"key":"8_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104782","volume":"177","author":"AFA Hussein","year":"2020","unstructured":"Hussein AFA, Cheng H, Tundup S, Antanasijevic A, Varhegyi E, Perez J, AbdulRahman EM, Elenany MG, Helal S, Caffrey M, Peet N, Manicassamy B, Rong L (2020) Identification of entry inhibitors with 4-aminopiperidine scaffold targeting group 1 influenza A virus. Antivir Res 177:104782. https:\/\/doi.org\/10.1016\/j.antiviral.2020.104782","journal-title":"Antivir Res"},{"issue":"24","key":"8_CR23","doi-asserted-by":"publisher","first-page":"11960","DOI":"10.1128\/jvi.01678-06","volume":"80","author":"JC Jones","year":"2006","unstructured":"Jones JC, Turpin EA, Bultmann H, Brandt CR, Schultz-Cherry S (2006) Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells. J Virol 80(24):11960\u201311967. https:\/\/doi.org\/10.1128\/jvi.01678-06","journal-title":"J Virol"},{"issue":"2","key":"8_CR24","doi-asserted-by":"publisher","first-page":"e00430","DOI":"10.1128\/mBio.00430-18","volume":"9","author":"JC Jones","year":"2018","unstructured":"Jones JC, Kumar G, Barman S, Najera I, White SW, Webby RJ, Govorkova EA (2018) Identification of the I38T PA substitution as a resistance marker for next-generation influenza virus endonuclease inhibitors. MBio 9(2):e00430. https:\/\/doi.org\/10.1128\/mBio.00430-18","journal-title":"MBio"},{"issue":"2","key":"8_CR25","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1073\/pnas.1617020114","volume":"114","author":"RU Kadam","year":"2017","unstructured":"Kadam RU, Wilson IA (2017) Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol. Proc Natl Acad Sci U S A 114(2):206\u2013214. https:\/\/doi.org\/10.1073\/pnas.1617020114","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"8_CR26","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.3390\/molecules23102475","volume":"23","author":"K Kaihatsu","year":"2018","unstructured":"Kaihatsu K, Yamabe M, Ebara Y (2018) Antiviral mechanism of action of epigallocatechin-3-O-gallate and its fatty acid esters. Molecules 23(10):2475. https:\/\/doi.org\/10.3390\/molecules23102475","journal-title":"Molecules"},{"issue":"2","key":"8_CR27","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.antiviral.2013.08.002","volume":"100","author":"M Kim","year":"2013","unstructured":"Kim M, Kim SY, Lee HW, Shin JS, Kim P, Jung YS, Jeong HS, Hyun JK, Lee CK (2013) Inhibition of influenza virus internalization by (-)-epigallocatechin-3-gallate. Antivir Res 100(2):460\u2013472. https:\/\/doi.org\/10.1016\/j.antiviral.2013.08.002","journal-title":"Antivir Res"},{"issue":"17","key":"8_CR28","doi-asserted-by":"publisher","first-page":"e00878","DOI":"10.1128\/jvi.00878-19","volume":"93","author":"JI Kim","year":"2019","unstructured":"Kim JI, Lee S, Lee GY, Park S, Bae JY, Heo J, Kim HY, Woo SH, Lee HU, Ahn CA, Bang HJ, Ju HS, Ok K, Byun Y, Cho DJ, Shin JS, Kim DY, Park MS, Park MS (2019) Novel small molecule targeting the hemagglutinin stalk of influenza viruses. J Virol 93(17):e00878. https:\/\/doi.org\/10.1128\/jvi.00878-19","journal-title":"J Virol"},{"issue":"1","key":"8_CR29","doi-asserted-by":"publisher","first-page":"88","DOI":"10.17116\/terarkh201587188-96","volume":"87","author":"OI Kiselev","year":"2015","unstructured":"Kiselev OI, Maleev VV, Deeva EG, Leneva IA, Selkova EP, Osipova EA, Obukhov AA, Nadorov SA, Kulikova EV (2015) Clinical efficacy of arbidol (umifenovir) in the therapy of influenza in adults: preliminary results of the multicenter double-blind randomized placebo-controlled study ARBITR. Ter Arkh 87(1):88\u201396. https:\/\/doi.org\/10.17116\/terarkh201587188-96","journal-title":"Ter Arkh"},{"issue":"8","key":"8_CR30","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1016\/j.celrep.2019.10.064","volume":"29","author":"GP Larson","year":"2019","unstructured":"Larson GP, Tran V, Y\u00fa S, Ca\u00ec Y, Higgins CA, Smith DM, Baker SF, Radoshitzky SR, Kuhn JH, Mehle A (2019) EPS8 facilitates uncoating of influenza A virus. Cell Rep 29(8):2175\u20132183.e2174. https:\/\/doi.org\/10.1016\/j.celrep.2019.10.064","journal-title":"Cell Rep"},{"issue":"3","key":"8_CR31","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.antiviral.2013.03.021","volume":"98","author":"NS Laursen","year":"2013","unstructured":"Laursen NS, Wilson IA (2013) Broadly neutralizing antibodies against influenza viruses. Antivir Res 98(3):476\u2013483. https:\/\/doi.org\/10.1016\/j.antiviral.2013.03.021","journal-title":"Antivir Res"},{"issue":"8","key":"8_CR32","first-page":"84","volume":"77","author":"IA Leneva","year":"2005","unstructured":"Leneva IA, Fediakina IT, Gus\u2019kova TA, Glushkov RG (2005) Sensitivity of various influenza virus strains to arbidol. Influence of arbidol combination with different antiviral drugs on reproduction of influenza virus A. Ter Arkh 77(8):84\u201388","journal-title":"Ter Arkh"},{"issue":"8","key":"8_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0041956","volume":"7","author":"R Li","year":"2012","unstructured":"Li R, Song D, Zhu Z, Xu H, Liu S (2012) An induced pocket for the binding of potent fusion inhibitor CL-385319 with H5N1 influenza virus hemagglutinin. PLoS One 7(8):e41956. https:\/\/doi.org\/10.1371\/journal.pone.0041956","journal-title":"PLoS One"},{"issue":"3","key":"8_CR34","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/irv.12449","volume":"11","author":"ZN Li","year":"2017","unstructured":"Li ZN, Trost JF, Weber KM, LeMasters EH, Nasreen S, Esfandiari J, Gunasekera AH, McCausland M, Sturm-Ramirez K, Wrammert J, Gregory S, Veguilla V, Stevens J, Miller JD, Katz JM, Levine MZ (2017) Novel multiplex assay platforms to detect influenza A hemagglutinin subtype-specific antibody responses for high-throughput and in-field applications. Influenza Other Respir Viruses 11(3):289\u2013297. https:\/\/doi.org\/10.1111\/irv.12449","journal-title":"Influenza Other Respir Viruses"},{"issue":"9","key":"8_CR35","doi-asserted-by":"publisher","first-page":"5437","DOI":"10.1128\/aac.00607-16","volume":"60","author":"JJ Lim","year":"2016","unstructured":"Lim JJ, Deng R, Derby MA, Larouche R, Horn P, Anderson M, Maia M, Carrier S, Pelletier I, Burgess T, Kulkarni P, Newton E, Tavel JA (2016) Two phase 1, randomized, double-blind, placebo-controlled, single-ascending-dose studies to investigate the safety, tolerability, and pharmacokinetics of an anti-influenza A virus monoclonal antibody, MHAA4549A, in healthy volunteers. Antimicrob Agents Chemother 60(9):5437\u20135444. https:\/\/doi.org\/10.1128\/aac.00607-16","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"8_CR36","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.1021\/acs.molpharmaceut.8b00531","volume":"15","author":"T Liu","year":"2018","unstructured":"Liu T, Liu M, Chen F, Chen F, Tian Y, Huang Q, Liu S, Yang J (2018) A small-molecule compound has anti-influenza A virus activity by acting as a \u201cPB2 Inhibitor\u201d. Mol Pharm 15(9):4110\u20134120. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00531","journal-title":"Mol Pharm"},{"key":"8_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173748","volume":"891","author":"AS Lokhande","year":"2021","unstructured":"Lokhande AS, Devarajan PV (2021) A review on possible mechanistic insights of Nitazoxanide for repurposing in COVID-19. Eur J Pharmacol 891:173748. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173748","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"8_CR38","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1128\/jvi.71.5.4062-4070.1997","volume":"71","author":"G Luo","year":"1997","unstructured":"Luo G, Torri A, Harte WE, Danetz S, Cianci C, Tiley L, Day S, Mullaney D, Yu KL, Ouellet C, Dextraze P, Meanwell N, Colonno R, Krystal M (1997) Molecular mechanism underlying the action of a novel fusion inhibitor of influenza A virus. J Virol 71(5):4062\u20134070. https:\/\/doi.org\/10.1128\/jvi.71.5.4062-4070.1997","journal-title":"J Virol"},{"issue":"12","key":"8_CR39","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1093\/infdis\/jis622","volume":"206","author":"RB Moss","year":"2012","unstructured":"Moss RB, Hansen C, Sanders RL, Hawley S, Li T, Steigbigel RT (2012) A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection. J Infect Dis 206(12):1844\u20131851. https:\/\/doi.org\/10.1093\/infdis\/jis622","journal-title":"J Infect Dis"},{"key":"8_CR40","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/1743-422x-10-118","volume":"10","author":"Y Motohashi","year":"2013","unstructured":"Motohashi Y, Igarashi M, Okamatsu M, Noshi T, Sakoda Y, Yamamoto N, Ito K, Yoshida R, Kida H (2013) Antiviral activity of stachyflin on influenza A viruses of different hemagglutinin subtypes. Virol J 10:118. https:\/\/doi.org\/10.1186\/1743-422x-10-118","journal-title":"Virol J"},{"issue":"4","key":"8_CR41","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.3892\/etm.2020.9047","volume":"20","author":"Q Mou","year":"2020","unstructured":"Mou Q, Jiang Y, Zhu L, Zhu Z, Ren T (2020) EGCG induces \u03b2-defensin 3 against influenza A virus H1N1 by the MAPK signaling pathway. Exp Ther Med 20(4):3017\u20133024. https:\/\/doi.org\/10.3892\/etm.2020.9047","journal-title":"Exp Ther Med"},{"issue":"2","key":"8_CR42","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.antiviral.2013.08.021","volume":"100","author":"ZH Nasser","year":"2013","unstructured":"Nasser ZH, Swaminathan K, M\u00fcller P, Downard KM (2013) Inhibition of influenza hemagglutinin with the antiviral inhibitor arbidol using a proteomics based approach and mass spectrometry. Antivir Res 100(2):399\u2013406. https:\/\/doi.org\/10.1016\/j.antiviral.2013.08.021","journal-title":"Antivir Res"},{"issue":"Pt 5","key":"8_CR43","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1099\/vir.0.038679-0","volume":"93","author":"MQ Nicol","year":"2012","unstructured":"Nicol MQ, Ligertwood Y, Bacon MN, Dutia BM, Nash AA (2012) A novel family of peptides with potent activity against influenza A viruses. J Gen Virol 93(Pt 5):980\u2013986. https:\/\/doi.org\/10.1099\/vir.0.038679-0","journal-title":"J Gen Virol"},{"issue":"10","key":"8_CR44","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1021\/acsinfecdis.9b00230","volume":"5","author":"R O\u2019Hanlon","year":"2019","unstructured":"O\u2019Hanlon R, Leyva-Grado VH, Sourisseau M, Evans MJ, Shaw ML (2019) An influenza virus entry inhibitor targets class II PI3 kinase and synergizes with oseltamivir. ACS Infect Dis 5(10):1779\u20131793. https:\/\/doi.org\/10.1021\/acsinfecdis.9b00230","journal-title":"ACS Infect Dis"},{"issue":"3","key":"8_CR45","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1093\/infdis\/jix292","volume":"216","author":"CI Paules","year":"2017","unstructured":"Paules CI, Lakdawala S, McAuliffe JM, Paskel M, Vogel L, Kallewaard NL, Zhu Q, Subbarao K (2017) The hemagglutinin A stem antibody MEDI8852 prevents and controls disease and limits transmission of pandemic influenza viruses. J Infect Dis 216(3):356\u2013365. https:\/\/doi.org\/10.1093\/infdis\/jix292","journal-title":"J Infect Dis"},{"issue":"6","key":"8_CR46","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1128\/jvi.02077-15","volume":"90","author":"EI P\u00e9cheur","year":"2016","unstructured":"P\u00e9cheur EI, Borisevich V, Halfmann P, Morrey JD, Smee DF, Prichard M, Mire CE, Kawaoka Y, Geisbert TW, Polyak SJ (2016) The synthetic antiviral drug arbidol inhibits globally prevalent pathogenic viruses. J Virol 90(6):3086\u20133092. https:\/\/doi.org\/10.1128\/jvi.02077-15","journal-title":"J Virol"},{"issue":"2","key":"8_CR47","doi-asserted-by":"publisher","first-page":"e01639","DOI":"10.1128\/jvi.01639-18","volume":"93","author":"KL Prachanronarong","year":"2019","unstructured":"Prachanronarong KL, Canale AS, Liu P, Somasundaran M, Hou S, Poh YP, Han T, Zhu Q, Renzette N, Zeldovich KB, Kowalik TF, Kurt-Yilmaz N, Jensen JD, Bolon DNA, Marasco WA, Finberg RW, Schiffer CA, Wang JP (2019) Mutations in influenza A virus neuraminidase and hemagglutinin confer resistance against a broadly neutralizing hemagglutinin stem antibody. J Virol 93(2):e01639. https:\/\/doi.org\/10.1128\/jvi.01639-18","journal-title":"J Virol"},{"key":"8_CR48","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.antiviral.2014.07.014","volume":"110","author":"JF Rossignol","year":"2014","unstructured":"Rossignol JF (2014) Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antivir Res 110:94\u2013103. https:\/\/doi.org\/10.1016\/j.antiviral.2014.07.014","journal-title":"Antivir Res"},{"issue":"43","key":"8_CR49","doi-asserted-by":"publisher","first-page":"29798","DOI":"10.1074\/jbc.M109.029470","volume":"284","author":"JF Rossignol","year":"2009","unstructured":"Rossignol JF, La Frazia S, Chiappa L, Ciucci A, Santoro MG (2009) Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J Biol Chem 284(43):29798\u201329808. https:\/\/doi.org\/10.1074\/jbc.M109.029470","journal-title":"J Biol Chem"},{"issue":"11","key":"8_CR50","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s40265-020-01350-8","volume":"80","author":"M Shirley","year":"2020","unstructured":"Shirley M (2020) Baloxavir marboxil: a review in acute uncomplicated influenza. Drugs 80(11):1109\u20131118. https:\/\/doi.org\/10.1007\/s40265-020-01350-8","journal-title":"Drugs"},{"issue":"1","key":"8_CR51","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1128\/jvi.77.1.460-469.2003","volume":"77","author":"SB Sieczkarski","year":"2003","unstructured":"Sieczkarski SB, Brown HA, Whittaker GR (2003) Role of protein kinase C betaII in influenza virus entry via late endosomes. J Virol 77(1):460\u2013469. https:\/\/doi.org\/10.1128\/jvi.77.1.460-469.2003","journal-title":"J Virol"},{"key":"8_CR52","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1146\/annurev.biochem.69.1.531","volume":"69","author":"JJ Skehel","year":"2000","unstructured":"Skehel JJ, Wiley DC (2000) Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 69:531\u2013569. https:\/\/doi.org\/10.1146\/annurev.biochem.69.1.531","journal-title":"Annu Rev Biochem"},{"key":"8_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104763","volume":"184","author":"SE Sloan","year":"2020","unstructured":"Sloan SE, Szretter KJ, Sundaresh B, Narayan KM, Smith PF, Skurnik D, Bedard S, Trevejo JM, Oldach D, Shriver Z (2020) Clinical and virological responses to a broad-spectrum human monoclonal antibody in an influenza virus challenge study. Antivir Res 184:104763. https:\/\/doi.org\/10.1016\/j.antiviral.2020.104763","journal-title":"Antivir Res"},{"issue":"2","key":"8_CR54","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.antiviral.2005.06.010","volume":"68","author":"JM Song","year":"2005","unstructured":"Song JM, Lee KH, Seong BL (2005) Antiviral effect of catechins in green tea on influenza virus. Antivir Res 68(2):66\u201374. https:\/\/doi.org\/10.1016\/j.antiviral.2005.06.010","journal-title":"Antivir Res"},{"issue":"8","key":"8_CR55","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1021\/ml2000627","volume":"2","author":"G Tang","year":"2011","unstructured":"Tang G, Lin X, Qiu Z, Li W, Zhu L, Wang L, Li S, Li H, Lin W, Yang M, Guo T, Chen L, Lee D, Wu JZ, Yang W (2011) Design and synthesis of benzenesulfonamide derivatives as potent anti-influenza hemagglutinin inhibitors. ACS Med Chem Lett 2(8):603\u2013607. https:\/\/doi.org\/10.1021\/ml2000627","journal-title":"ACS Med Chem Lett"},{"key":"8_CR56","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jim.2014.03.023","volume":"410","author":"RR Thangavel","year":"2014","unstructured":"Thangavel RR, Bouvier NM (2014) Animal models for influenza virus pathogenesis, transmission, and immunology. J Immunol Methods 410:60\u201379. https:\/\/doi.org\/10.1016\/j.jim.2014.03.023","journal-title":"J Immunol Methods"},{"issue":"5","key":"8_CR57","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.chom.2014.04.009","volume":"15","author":"K Tharakaraman","year":"2014","unstructured":"Tharakaraman K, Subramanian V, Cain D, Sasisekharan V, Sasisekharan R (2014) Broadly neutralizing influenza hemagglutinin stem-specific antibody CR8020 targets residues that are prone to escape due to host selection pressure. Cell Host Microbe 15(5):644\u2013651. https:\/\/doi.org\/10.1016\/j.chom.2014.04.009","journal-title":"Cell Host Microbe"},{"issue":"12","key":"8_CR58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003942","volume":"3","author":"M Throsby","year":"2008","unstructured":"Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, Cornelissen L, Bakker A, Cox F, van Deventer E, Guan Y, Cinatl J, ter Meulen J, Lasters I, Carsetti R, Peiris M, de Kruif J, Goudsmit J (2008) Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 3(12):e3942. https:\/\/doi.org\/10.1371\/journal.pone.0003942","journal-title":"PLoS One"},{"issue":"6","key":"8_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199683","volume":"13","author":"JF Trost","year":"2018","unstructured":"Trost JF, LeMasters EH, Liu F, Carney P, Lu X, Sugawara K, Hongo S, Stevens J, Steinhauer DA, Tumpey T, Katz JM, Levine MZ, Li ZN (2018) Development of a high-throughput assay to detect antibody inhibition of low pH induced conformational changes of influenza virus hemagglutinin. PLoS One 13(6):e0199683. https:\/\/doi.org\/10.1371\/journal.pone.0199683","journal-title":"PLoS One"},{"key":"8_CR60","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ijid.2020.11.142","volume":"103","author":"ZF Udwadia","year":"2021","unstructured":"Udwadia ZF, Singh P, Barkate H, Patil S, Rangwala S, Pendse A, Kadam J, Wu W, Caracta CF, Tandon M (2021) Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int J Infect Dis 103:62\u201371. https:\/\/doi.org\/10.1016\/j.ijid.2020.11.142","journal-title":"Int J Infect Dis"},{"key":"8_CR61","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41421-020-0169-8","volume":"6","author":"X Wang","year":"2020","unstructured":"Wang X, Cao R, Zhang H, Liu J, Xu M, Hu H, Li Y, Zhao L, Li W, Sun X, Yang X, Shi Z, Deng F, Hu Z, Zhong W, Wang M (2020a) The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discov 6:28. https:\/\/doi.org\/10.1038\/s41421-020-0169-8","journal-title":"Cell Discov"},{"issue":"10","key":"8_CR62","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1093\/infdis\/jiz656","volume":"221","author":"Y Wang","year":"2020","unstructured":"Wang Y, Fan G, Salam A, Horby P, Hayden FG, Chen C, Pan J, Zheng J, Lu B, Guo L, Wang C, Cao B (2020b) Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection. J Infect Dis 221(10):1688\u20131698. https:\/\/doi.org\/10.1093\/infdis\/jiz656","journal-title":"J Infect Dis"},{"issue":"15","key":"8_CR63","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/cid\/ciaa272","volume":"71","author":"Z Wang","year":"2020","unstructured":"Wang Z, Yang B, Li Q, Wen L, Zhang R (2020c) Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis 71(15):769\u2013777. https:\/\/doi.org\/10.1093\/cid\/ciaa272","journal-title":"Clin Infect Dis"},{"issue":"2","key":"8_CR64","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ymeth.2011.09.002","volume":"55","author":"MA Whitt","year":"2011","unstructured":"Whitt MA, Mire CE (2011) Utilization of fluorescently-labeled tetracysteine-tagged proteins to study virus entry by live cell microscopy. Methods 55(2):127\u2013136. https:\/\/doi.org\/10.1016\/j.ymeth.2011.09.002","journal-title":"Methods"},{"key":"8_CR65","unstructured":"WHO (2018) Influenza (seasonal). www.who.int\/mediacentre\/factsheets\/fs211\/en\/"},{"issue":"2","key":"8_CR66","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.antiviral.2009.04.012","volume":"83","author":"A Wolkerstorfer","year":"2009","unstructured":"Wolkerstorfer A, Kurz H, Bachhofner N, Szolar OH (2009) Glycyrrhizin inhibits influenza A virus uptake into the cell. Antivir Res 83(2):171\u2013178. https:\/\/doi.org\/10.1016\/j.antiviral.2009.04.012","journal-title":"Antivir Res"},{"issue":"2","key":"8_CR67","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41594-018-0025-9","volume":"25","author":"NC Wu","year":"2018","unstructured":"Wu NC, Wilson IA (2018) Structural insights into the design of novel anti-influenza therapies. Nat Struct Mol Biol 25(2):115\u2013121. https:\/\/doi.org\/10.1038\/s41594-018-0025-9","journal-title":"Nat Struct Mol Biol"},{"issue":"1","key":"8_CR68","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/v8010006","volume":"8","author":"W Wu","year":"2015","unstructured":"Wu W, Li R, Li X, He J, Jiang S, Liu S, Yang J (2015a) Quercetin as an antiviral agent inhibits influenza A virus (IAV) entry. Viruses 8(1):6. https:\/\/doi.org\/10.3390\/v8010006","journal-title":"Viruses"},{"issue":"9","key":"8_CR69","doi-asserted-by":"publisher","first-page":"e0138426","DOI":"10.1371\/journal.pone.0138426","volume":"10","author":"W Wu","year":"2015","unstructured":"Wu W, Lin D, Shen X, Li F, Fang Y, Li K, Xun T, Yang G, Yang J, Liu S, He J (2015b) New influenza A virus entry inhibitors derived from the viral fusion peptides. PLoS One 10(9):e0138426. https:\/\/doi.org\/10.1371\/journal.pone.0138426","journal-title":"PLoS One"},{"key":"8_CR70","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.intimp.2017.08.023","volume":"52","author":"MJ Xu","year":"2017","unstructured":"Xu MJ, Liu BJ, Wang CL, Wang GH, Tian Y, Wang SH, Li J, Li PY, Zhang RH, Wei D, Tian SF, Xu T (2017) Epigallocatechin-3-gallate inhibits TLR4 signaling through the 67-kDa laminin receptor and effectively alleviates acute lung injury induced by H9N2 swine influenza virus. Int Immunopharmacol 52:24\u201333. https:\/\/doi.org\/10.1016\/j.intimp.2017.08.023","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"8_CR71","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1080\/13543784.2019.1606210","volume":"28","author":"J Yang","year":"2019","unstructured":"Yang J, Huang Y, Liu S (2019) Investigational antiviral therapies for the treatment of influenza. Expert Opin Investig Drugs 28(5):481\u2013488. https:\/\/doi.org\/10.1080\/13543784.2019.1606210","journal-title":"Expert Opin Investig Drugs"},{"key":"8_CR72","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3390\/v11050405","volume":"11","author":"Z Yun","year":"2019","unstructured":"Yun Z, Cong X, Hao Z, George Dacai L, Chunyi X, Yongchang C (2019) Targeting hemagglutinin: approaches for broad protection against the influenza A virus. Viruses 11:405. https:\/\/doi.org\/10.3390\/v11050405","journal-title":"Viruses"},{"key":"8_CR73","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.antiviral.2015.09.008","volume":"123","author":"JM Zenilman","year":"2015","unstructured":"Zenilman JM, Fuchs EJ, Hendrix CW, Radebaugh C, Jurao R, Nayak SU, Hamilton RG, McLeod Griffiss J (2015) Phase 1 clinical trials of DAS181, an inhaled sialidase, in healthy adults. Antivir Res 123:114\u2013119. https:\/\/doi.org\/10.1016\/j.antiviral.2015.09.008","journal-title":"Antivir Res"},{"key":"8_CR74","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.tifs.2021.05.023","volume":"114","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Zhang X, Bi K, He Y, Yan W, Yang CS, Zhang J (2021) Potential protective mechanisms of green tea polyphenol EGCG against COVID-19. Trends Food Sci Technol 114:11\u201324. https:\/\/doi.org\/10.1016\/j.tifs.2021.05.023","journal-title":"Trends Food Sci Technol"},{"issue":"12","key":"8_CR75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029120","volume":"6","author":"L Zhu","year":"2011","unstructured":"Zhu L, Li Y, Li S, Li H, Qiu Z, Lee C, Lu H, Lin X, Zhao R, Chen L, Wu JZ, Tang G, Yang W (2011) Inhibition of influenza A virus (H1N1) fusion by benzenesulfonamide derivatives targeting viral hemagglutinin. PLoS One 6(12):e29120. https:\/\/doi.org\/10.1371\/journal.pone.0029120","journal-title":"PLoS One"}],"container-title":["Advances in Experimental Medicine and Biology","Virus Entry Inhibitors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-981-16-8702-0_8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T09:34:16Z","timestamp":1649756056000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-981-16-8702-0_8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9789811687013","9789811687020"],"references-count":75,"URL":"https:\/\/doi.org\/10.1007\/978-981-16-8702-0_8","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"13 April 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}